Table 1.

Clinical demographics of training and validation cohorts.

	Initial diagnosis				Surveillance
Cohort	Train		Validation		Train		Validation
Cancer Status	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive
No. subjects	139	56	96	22	100	38	82	48
Median age (IQR)	62 (31)	75 (16)	65 (24)	70 (17)	72 (14)	77 (13)	72 (13)	69 (13)
Sex (%)
Male/female	55/45	71/29	65/35	73/27	74/26	82/18	77/23	71/29
Race (%)
White	58	55	60	59	75	55	78	79
Black or African American	12	14	11	9	7	8	7	15
Asian	16	9	18	9	14	19	7	4
American Indian or Alaska Native	1	2	1	0	1	0	0	0
Hispanic or Latino	2	0	1	0	1	0	4	0
other	11	20	9	23	2	18	4	2
Smoking History (%)
Current	10	7	5	14	7	3	15	13
Former	18	14	26	45	36	47	52	50
Never	62	20	69	41	55	32	32	38
Unknown	10	59	0	0	2	18	1	0
Urologic comorbidities (%)a
UTI	17	0	10	5	13	3	1	4
LUTS	21	11	21	18	27	8	16	2
BPH	16	9	27	5	41	24	24	8
Kidney stone history (%)
Current	10	0	5	5	2	3	1	0
Past	16	4	11	0	5	3	1	2
Urine chemistry/microscopy (%)a
Hematuria	50	23	39	50	31	24	2	10
Leukocytes	35	13	15	5	25	16	1	6
Grade (%)b
LG	—	25	—	36	45	47	49	65
HG	—	75	—	64	32	45	51	35
Unknown	—		—		23	8	0	0
Stage (%)b
Cis	—	5	—	0	6	5	7	11
Ta	—	38	—	68	51	58	71	79
T1	—	25	—	14	15	8	17	8
T2	—	29	—	18	3	11	3	2
Unknown	—	4	—	0	25	18	2	0

^aAs reported at the time of sample collection, >1+ urine microscopy or >3 RBC/hpf or any gross.

^bGrade and stage of surveillance negatives indicate the pathology of the primary tumor.